Balancing Cost, Innovation and Incentives: The R&D Subcontracting Challenge for UK Businesses
The Value of UK R&D Investment
For UK businesses, Research and Development (R&D) remains fundamental to growth, innovation and long‑term competitiveness. The government recognises this, offering generous tax incentives to encourage domestic investment.
Yet the global R&D environment is shifting. Rising costs in developed markets and increasing capability in overseas hubs are motivating companies to rethink where their R&D takes place.
The Attraction of Lower‑Cost Overseas R&D
Providers such as WuXi Biologics in China, which offers services from discovery through to biologics manufacturing have become a popular choice for life sciences companies seeking to accelerate innovation. Projects delivered through WuXi Biologics can be up to 40% cheaper than equivalent UK‑based work, driven by lower labour costs, reduced infrastructure needs and competitive project budgets.
Importantly, overseas subcontracting is not limited to external providers like WuXi Biologics. Many UK groups also channel R&D through their own overseas subsidiaries, where specialist teams or facilities already exist. This can streamline global operations, but it raises the same challenges around UK R&D tax relief eligibility when significant activity is performed outside the UK.
The Strategic Trade‑Off
The decision to shift R&D overseas is rarely straightforward. While cost savings can be significant, companies must weigh them against long‑term strategic factors, including:
- quality control and regulatory oversight
- intellectual property protection
- data sensitivity and patient safety
- alignment with corporate strategy
- management complexity across borders and time zones
For highly regulated sectors such as life sciences, ensuring overseas facilities meet domestic standards is essential.
Tax Implications and Policy Misalignment
The UK’s R&D tax relief system is designed to reward activity that benefits the UK economy. Extensive overseas R&D activities whether via third parties or group subsidiaries can reduce eligibility or limit the available benefit.
Currently, overseas subcontracting is often more cost‑effective than UK‑based subcontracting, creating a disconnect between policy intent and commercial reality. This tension influences where organisations choose to locate significant elements of their R&D pipeline.
A Hybrid Model: Cost Efficiency Without Strategic Compromise
Many companies adopt a hybrid approach, conducting high‑value, strategically important research in the UK while outsourcing routine or large‑scale tasks overseas. For example:
- UK‑based teams lead drug discovery, experimental design and early development
- Overseas hubs deliver routine testing or high‑volume manufacturing simulations
This allows businesses to maintain scientific leadership and intellectual control while capturing cost efficiencies where appropriate.
Why Domestic R&D Still Matters
Investing in UK‑based R&D provides benefits that extend beyond a single project:
- stronger intellectual property ownership
- more responsive decision‑making
- closer alignment with strategic priorities
- access to UK talent and academic partnerships
- faster iteration cycles
More broadly, domestic R&D supports employment, supply chains, universities and start‑ups. Its multiplier effect strengthens the UK’s innovation ecosystem in ways that overseas R&D cannot replicate.
The Role of Government Strategy
The UK government has acknowledged the importance of strengthening the domestic R&D environment through the UK Life Sciences Strategy, built around three pillars:
- Driving innovation
- Accelerating access to therapies
- Strengthening research and manufacturing capabilities
Actions include investment in clinical trials infrastructure, advanced manufacturing and AI‑enabled drug discovery, alongside policies to enhance collaboration between industry, academia and the NHS.
These steps are positive, but incentives still favour overseas subcontracting.
A Policy Opportunity: Rewarding UK Subcontracting
There is a clear opportunity for policymakers to rebalance incentives by making UK‑based subcontracting more competitive. Options include:
- enhanced tax relief for domestic subcontracted R&D
- targeted grants for UK‑based CROs and specialist labs
- incentives that recognise the broader economic contribution of domestic R&D activity
Such changes would encourage both UK‑headquartered firms and international partners to keep more of their R&D and the associated economic value within the UK.
Conclusion
Overseas hubs like WuXi Biologics offer substantial cost advantages, and in some cases, these savings are critical. However, UK R&D incentives exist to support domestic innovation, and the most effective approach for many companies is a hybrid model that balances cost efficiencies with strategic control.
To fully align policy with the ambitions of the UK Life Sciences Strategy, the government could enhance support for UKbased subcontracting. Doing so would help bridge the current cost gap with overseas hubs, strengthen the UK’s competitive position and ensure that more of the longterm value generated by R&D remains within the UK.
For organisations seeking support that combines scientific depth with tax technical expertise, Frazier & Deeter brings extensive experience across the full research and development process. Our team works closely with life sciences businesses to prepare, review and strengthen claims. To explore your specific challenges or discuss how we can support your organisation, we invite you to connect with our team.
Contributors
Asma Aslam, Senior Tax Manager, Frazier & Deeter UK
Explore related insights
-
Interplay of UK VAT with Intercompany Operating Models
Read more: Interplay of UK VAT with Intercompany Operating Models
-
How to Account for Employee Share Options Under FRS 102
Read more: How to Account for Employee Share Options Under FRS 102
